Case Report Study of Integrated Treatment with T-AYU-HM Premium in a Child of Sickle Cell Disease: A 7 Year Follow up Study

Published on:October 2022

Indian Journal of Pharmacy Practice, 2022; 15(4):325-330

Case Report | doi:10.5530/ijopp.15.4.59

Authors:

Atul Desai^1,*, Kavita Desai¹, Hemshree Desai², Rutvij Desai³, Chirag Desai⁴, Pinky Purohit⁴, Nikita Champaneri⁴, Anali Patel⁴, Pragna Mahida⁵

¹Dhanvantari Clinic, Ayurveda Healthcare and Research Centre, Vyara, Gujarat, INDIA.

²Master’s Students in Public Health, University of Glasgow, Scotland, UK.

³Student of Medicine, Manila Central University, Caloocan, PHILIPPINES.

⁴Department of Pharmacology, ROFEL Shri G M Bilakhia College of Pharmacy, Vapi, Chandor, Vapi, Gujarat,  INDIA.

⁵Pathologist, Raj Pathology Laboratory, Vyara, Gujarat, INDIA.

Abstract:

Sickle cell anemia is a type of hemoglobin disorder that no longer requires an introduction to countries like India, Africa, and America. Although the pathogenesis is identified and well defined the clinical picture of symptoms is varied amongst patients. Diagnosis and management of sickle cell trait and disease in children are still a main concern for medical healthcare. In this case report, we present a case exhibiting the impact of integrated therapy on the clinical response of a child suffering from sickle cell disease. A boy X is currently 14 years old was presented to the clinic at 2014 when he was 7 years old. He was diagnosed sickle cell disease during screening. Due to which he was suffering from painful complications and hospitalizations and repeated blood transfusions. With prior information and consent the integrated treatment including T-AYU-HM Premium 300mg started. The overall condition of the child improved and sustained throughout the treatment period. The integrated treatment has reduced the burden of the length of hospital stay and its expanses, requirement of blood transfusion, and complications associated with the vaso-occlusive crisis. The case evaluation suggested the child was admitted only a couple of times in seven years of treatment indicating no major complications were presented during this period. The key observation was sustained hemoglobin and red blood corpuscle concentration prevented the requirement of blood transfusion in sickle cell anemia patients. This approach was a cost-effective, safer as no untoward reaction reported, and therapeutically potential in the management of children suffering from sickle cell anemia.

Keywords: Sickle cell anemia, T-AYU-HM Premium, Integrated treatment, Hemoglobin disorder.